Modality
Degrader
MOA
PD-L1i
Target
CD3
Pathway
Tau
Wet AMDSLELN
Development Pipeline
Preclinical
~Jul 2014
→ ~Oct 2015
Phase 1
~Jan 2016
→ ~Apr 2017
Phase 2
~Jul 2017
→ ~Oct 2018
Phase 3
~Jan 2019
→ ~Apr 2020
NDA/BLA
~Jul 2020
→ ~Oct 2021
Approved
Jan 2022
→ Aug 2030
ApprovedCurrent
NCT07331355
2,945 pts·LN
2022-01→2030-08·Terminated
NCT05964807
2,617 pts·LN
2022-06→2030-02·Active
5,562 total pts1 indication
CompletedCurrentUpcoming
Catalysts (2)
2030-02-263.9y awayPh3 Readout· LN
2030-08-194.4y awayPh3 Readout· LN
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Approved
Termina…
Approved
Active
Catalysts
Ph3 Readout
2030-02-26 · 3.9y away
LN
Ph3 Readout
2030-08-19 · 4.4y away
LN
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07331355 | Approved | LN | Terminated | 2945 | EDSS |
| NCT05964807 | Approved | LN | Active | 2617 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| SRP-1135 | Sarepta | Phase 2/3 | MDM2 |